Litcius/Paper detail

Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial

Andrew Bivard, Henry Zhao, Leonid Churilov, Bruce C V Campbell, Skye Coote, Nawaf Yassi, Bernard Yan, Michael Valente, Angelos Sharobeam, Anna H Balabanski, Angela Dos Santos, Jo Lyn Ng, Vignan Yogendrakumar, Felix Ng, Francesca Langenberg, Damien Easton, Alex Warwick, Elizabeth Mackey, Amy MacDonald, Gagan Sharma, Michael Stephenson, Karen Smith, David Anderson, Philip Choi, Vincent Thijs, Henry Ma, Geoffrey C Cloud, Tissa Wijeratne, Liudmyla Olenko, Dominic Italiano, Stephen M Davis, Geoffrey A Donnan, Mark W Parsons

2022The Lancet Neurology135 citationsDOI

Topics & Concepts

TenecteplaseMedicineIschaemic strokeStroke (engine)Internal medicineCardiologyFibrinolytic agentThrombolysisTissue plasminogen activatorUnit (ring theory)Clinical trialPhase (matter)Pilot trialEmergency medicineIschemiaIschemic strokeVascular diseaseAcute Ischemic Stroke ManagementBlood Coagulation and Thrombosis MechanismsNeurological Disorders and Treatments
Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial | Litcius